Richard T Penson1, Kathleen M Moore2, Gini F Fleming3, Patricia Braly4, Veronica Schimp5, Hoa Nguyen6, Ursula A Matulonis7, Susana Banerjee8, Paul Haluska9, Martin Gore10, Diane C Bodurka11, Rebecca R Hozak12, Adarsh Joshi12, Yihuan Xu13, Jonathan D Schwartz13, William P McGuire14. 1. Massachusetts General Hospital for the Dana-Farber/Harvard Cancer Center, Boston, MA, USA. 2. University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3. University of Chicago Medical Center, Chicago, IL, USA. 4. Hematology and Oncology Specialists, LLC, Marrero, LA, USA. 5. MD Anderson Cancer Center, Orlando, FL, USA. 6. Gynecologic Oncology Associates, Inc., Hollywood, USA. 7. Dana-Farber Cancer Institute, Boston, MA, USA. 8. Royal Marsden Hospital, Surrey, England, UK. 9. Mayo Clinic, Rochester, MN, USA. 10. Royal Marsden Hospital, London, England, UK. 11. University of Texas MD Anderson Cancer Center, Houston, TX, USA. 12. Eli Lilly and Company, Indianapolis, IN, USA. 13. ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, Bridgewater, NJ, USA. 14. Inova Fairfax Hospital, Falls Church, VA, USA.
Abstract
OBJECTIVE: Vascular endothelial growth factor (VEGF) receptor-mediated signaling contributes to ovarian cancer pathogenesis. Elevated VEGF expression is associated with poor clinical outcomes. We investigated ramucirumab, a fully human anti-VEGFR-2 antibody, in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Primary endpoints were progression-free survival at 6 months (PFS-6) and confirmed objective response rate (ORR). METHODS: Women who received ≥ 1 platinum-based chemotherapeutic regimen and had a platinum-free interval of <12 months with measurable disease were eligible. Patients received 8 mg/kg ramucirumab intravenously every 2 weeks. RESULTS: Sixty patients were treated; one patient remained on study as of September 2013. The median age was 62 years (range: 27-80), and median number of prior regimens was 3. Forty-five (75%) patients had platinum refractory/resistant disease. Thirty-nine patients (65.0%) had serous tumors. PFS-6 was 25.0% (n=15/60, 95% CI: 14.7-37.9%). Best overall response was: partial response 5.0% (n=3/60), stable disease 56.7% (n=34/60), and progressive disease 33.3% (n=20/60). The most common treatment-emergent adverse events possibly related to study drug were headache (65.0%; 10.0% Grade ≥ 3), fatigue (56.7%; 3.3% Grade ≥ 3), diarrhea (28.3%; 1.7% Grade ≥ 3), hypertension (25.0%; 3.3% Grade ≥ 3), and nausea (20.0%; no Grade ≥ 3). Two patients experienced intestinal perforations (3.3% Grade ≥ 3). Pharmacodynamic analyses revealed changes in several circulating VEGF proteins following initial ramucirumab infusion, including increased VEGF-A, PlGF and decreased sVEGFR-2. CONCLUSIONS: Although antitumor activity was observed, the predetermined efficacy endpoints were not met.
OBJECTIVE:Vascular endothelial growth factor (VEGF) receptor-mediated signaling contributes to ovarian cancer pathogenesis. Elevated VEGF expression is associated with poor clinical outcomes. We investigated ramucirumab, a fully human anti-VEGFR-2 antibody, in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Primary endpoints were progression-free survival at 6 months (PFS-6) and confirmed objective response rate (ORR). METHODS:Women who received ≥ 1 platinum-based chemotherapeutic regimen and had a platinum-free interval of <12 months with measurable disease were eligible. Patients received 8 mg/kg ramucirumab intravenously every 2 weeks. RESULTS: Sixty patients were treated; one patient remained on study as of September 2013. The median age was 62 years (range: 27-80), and median number of prior regimens was 3. Forty-five (75%) patients had platinum refractory/resistant disease. Thirty-nine patients (65.0%) had serous tumors. PFS-6 was 25.0% (n=15/60, 95% CI: 14.7-37.9%). Best overall response was: partial response 5.0% (n=3/60), stable disease 56.7% (n=34/60), and progressive disease 33.3% (n=20/60). The most common treatment-emergent adverse events possibly related to study drug were headache (65.0%; 10.0% Grade ≥ 3), fatigue (56.7%; 3.3% Grade ≥ 3), diarrhea (28.3%; 1.7% Grade ≥ 3), hypertension (25.0%; 3.3% Grade ≥ 3), and nausea (20.0%; no Grade ≥ 3). Two patients experienced intestinal perforations (3.3% Grade ≥ 3). Pharmacodynamic analyses revealed changes in several circulating VEGF proteins following initial ramucirumab infusion, including increased VEGF-A, PlGF and decreased sVEGFR-2. CONCLUSIONS: Although antitumor activity was observed, the predetermined efficacy endpoints were not met.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Robert A Burger; Michael W Sill; Bradley J Monk; Benjamin E Greer; Joel I Sorosky Journal: J Clin Oncol Date: 2007-11-20 Impact factor: 44.544
Authors: Gabriel Osborn; Chara Stavraka; Rebecca Adams; Ahmad Sayasneh; Sharmistha Ghosh; Ana Montes; Katie E Lacy; Rebecca Kristeleit; James Spicer; Debra H Josephs; James N Arnold; Sophia N Karagiannis Journal: Clin Exp Immunol Date: 2022-07-22 Impact factor: 5.732
Authors: Marie Viala; Marie Vinches; Marie Alexandre; Caroline Mollevi; Anna Durigova; Nadia Hayaoui; Krisztian Homicsko; Alice Cuenant; Céline Gongora; Luca Gianni; Diego Tosi Journal: Br J Cancer Date: 2018-02-13 Impact factor: 7.640
Authors: Anuj Suri; Xiugui Sheng; Kevin M Schuler; Yan Zhong; Xiaoyun Han; Hannah M Jones; Paola A Gehrig; Chunxiao Zhou; Victoria L Bae-Jump Journal: Oncotarget Date: 2016-06-28